Target: Miles White, Chief Executive Officer of Abbott Laboratories
Goal: Encourage further research into finding a cure for hepatitis C
Pharmaceutical companies are quickly closing in on a cure for hepatitis C, new research indicates. As many as 170 million people around the world have been infected with hepatitis C, and of these, approximately three million Americans are currently living with the viral disease. At an annual meeting of the American Association for the Study of Liver Disease (AASLD), new data was presented that described mid-stage trials of a trio of drugs that may be the answer to the hepatitis C problem.
Hepatitis C, a viral disease that slowly attacks the liver over a number of years, is the main reason for liver transplants in the United States. For the most part, those who are infected largely rely on drugs containing an interferon—a treatment known to cause severe flu-like symptoms and unease among patients. Now, however, a trio of drugs is being tested that may eliminate the discomfort as well as the disease.
ABT-450 (a protease inhibitor), ABT-333 (a polymerase inhibitor) and ABT-267 act without an interferon and were shown in studies to have a 93 percent success rate among patients with the most common strain of hepatitis C, Genotype 1. “Nobody anywhere has broken the 50 percent mark in (cure rates) for this population,” explained Scott Brun, a senior research executive from Abbott Laboratories, the producer of the aforementioned drugs. “These are robust results.”
With cases of hepatitis C on the rise, new developments in treatment are even more necessary. Until hepatitis C is no longer a threat, pharmaceutical companies and laboratories must not give up on the search for a proper cure. Sign the petition below to encourage Abbott Laboratories to continue their work in finding a cure for hepatitis C.
Dear Mr. White,
The news is out and Abbott Laboratories is gaining ground in finding a cure for hepatitis C. With an estimated three million Americans infected with the viral disease, hepatitis C is currently the biggest reason for liver transplants in the country. But until recently, treatments were oftentimes uncomfortable and less than consistent.
Now, however, there is new hope that a cure may be found—and soon. In Abbott’s recent trials, hepatitis C may have finally met its match, and the news could not have come at a better time. With cases of the disease on the rise, a potential cure has been made all the more important. Because of these recent findings, I sign this petition to encourage Abbott Laboratories to continue its work in finding a cure for hepatitis C.
[Your Name Here]
Photo Credit: National Center for Advancing Translational Sciences (NCATS)